Sign in
Taking peopleNo phase

Blood tests for autoimmune hemolytic anemia in people with antiphospholipid syndrome

Uses blood tests to look for autoimmune hemolytic anemia in adults with antiphospholipid syndrome.

Key facts

Who runs it
New Valley University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Autoimmune Hemolytic Anemia and Its Clinical Implication on Antiphospholipid Syndrome
Status
Recruiting
People taking part
230 people, planned
Started
5 Jun 2026
Expected to end
15 Apr 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Hemoglobin
  • Coombs test
Record updated
10 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with antiphospholipid syndrome (an immune condition that causes blood clots or pregnancy problems) and anemia from red blood cell breakdown (hemolysis).

Age
18 years and older
Sex
All sexes
Disease stage
Diagnosed antiphospholipid syndrome, with anemia that fits hemolysis.

Main reasons for not taking part

  • Younger than 18 years
  • Anemia from causes other than autoimmune hemolysis

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Adults aged ≥18 years
  • Patients with anemia consistant with hemolysis
  • Patient diagnosed with antiphospholipid syndrome
  • Informed consent obtained

Who cannot take part

  • Other causes of anemia than autoimmune hemolysis
  • Age less than 18 years

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

AIHA is a heterogeneous autoimmune cytopenia with variable severity and significant morbidity. APS is defined by thrombosis and/or obstetric morbidity with persistent antiphospholipid antibodies (aPL).

The 2 groups in the trial

  • Antiphospholipid syndrome patients with AIHAExisting treatment, for comparison

    AIHA defined by: * Anemia plus hemolysis (↑LDH, ↑indirect bilirubin, ↓haptoglobin, reticulocytosis) and * Positive direct anti-globulin (Coombs) test , Drug induced hemolysis or other hereditary/acquired non immune hemolytic anemias.

    Treatment: Hemoglobin and Coombs test

  • Antiphospholipid syndrome patients without AIHAExisting treatment, for comparison

    Patients without hemolysis evidence

    Treatment: Hemoglobin and Coombs test

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Autoimmune Hemolytic Anemia and Its Clinical Implication on Antiphospholipid Syndrome
Plain-language title
Blood tests for autoimmune hemolytic anemia in people with antiphospholipid syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
10 August 2026